SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) July 6, 2022
PROMIS NEUROSCIENCES INC.
(Exact name of registrant as specified in its charter)
|(State or other jurisdiction||(Commission||(IRS Employer|
|of incorporation)||File Number)||Identification No.)|
Suite 200, 1920 Yonge Street, Toronto, Ontario
|(Address of principal executive offices)||(Zip Code)|
Registrant’s telephone number, including area code (416) 847-6898
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading Symbol(s)||Name of each exchange on which registered|
|Common Shares||PMN||The Nasdaq Capital Market|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter or Rule 12b-2 of the Securities Exchange Act of 1934) §140.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □
Item 8.01. Other Events
On July 6, 2022, The Nasdaq Stock Market LLC (the “Nasdaq”) approved ProMIS Neurosciences Inc.’s (the “Company”) application to list its common shares on The Nasdaq Capital Market. The Company’s common shares will begin trading on The Nasdaq Capital Market on July 8, 2022 under the symbol “PMN”. On July 8, 2022, the Company issued a press release announcing the Nasdaq listing. A copy of the press release is included as Exhibit 99.1 to this report.
Item 9.01. Financial Statement and Exhibits
|99.1||Press Release dated July 8, 2022|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|ProMIS Neurosciences Inc.|
|Date||July 8, 2022|
|/s/ Eugene Williams|
|Name: Eugene Williams|
|Title: Chairman and Chief Executive Officer|